Teva Pharmaceutical Industries Ltd (TEVA) Sees Large Drop in Short Interest
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 80,161,471 shares, a drop of 13.6% from the November 15th total of 92,803,223 shares. Based on an average daily volume of 24,072,035 shares, the days-to-cover ratio is currently 3.3 days.
Shares of Teva Pharmaceutical Industries (NYSE TEVA) opened at $18.61 on Monday. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $38.31. The stock has a market cap of $18,907.76, a price-to-earnings ratio of 4.30 and a beta of 0.55. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.
The business also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a $0.085 dividend. The ex-dividend date was Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 1.83%. Teva Pharmaceutical Industries’s dividend payout ratio is currently -12.10%.
Several equities analysts recently weighed in on TEVA shares. Cantor Fitzgerald set a $10.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Monday, November 27th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 4th. Goldman Sachs Group reiterated a “neutral” rating and issued a $21.00 price target (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, August 31st. BTIG Research upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Monday, September 11th. Finally, Morgan Stanley set a $15.00 price target on shares of Teva Pharmaceutical Industries and gave the stock an “underweight” rating in a report on Thursday, October 5th. Five equities research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus target price of $20.65.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-ltd-teva-sees-large-drop-in-short-interest/1770552.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.